kabutan

Kidswell Bio Corporation(4584) Summary

4584
TSE Growth
Kidswell Bio Corporation
223
JPY
-5
(-2.19%)
Apr 30, 11:29 am JST
1.39
USD
Apr 29, 10:29 pm EDT
Result
PTS
outside of trading hours
223.1
Apr 30, 11:29 am JST
Summary Chart Historical News Financial Result
PER
PBR
5.89
Yield
ー%
Margin Trading Ratio
Stock Price
Apr 30, 2026
Opening Apr 30, 9:00 am
226 JPY 1.41 USD
Previous Close Apr 28
228 JPY 1.43 USD
High Apr 30, 9:00 am
226 JPY 1.41 USD
Low Apr 30, 9:10 am
221 JPY 1.37 USD
Volume
176,400
Trading Value
0.04B JPY 0.25M USD
VWAP
222.83 JPY 1.39 USD
Minimum Trading Value
22,300 JPY 139 USD
Market Cap
0.01T JPY 0.07B USD
Number of Trades
114
Liquidity & Number of Trades
As of Apr 30, 2026
Liquidity
High
1-Year Average
1,118
1-Year High Jan 22, 2026
11,856
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 24, 2026 0 4,318,500
Apr 17, 2026 0 4,125,800
Apr 10, 2026 0 4,143,000
Apr 3, 2026 0 4,115,600
Mar 27, 2026 0 3,911,500
Company Profile
Kidswell Bio Corporation is a drug discovery venture originating from Hokkaido University. The company focuses on biopharmaceuticals, biosimilars, antibody drugs, and pediatric medicines.
Sector
Pharmaceuticals
Kidswell Bio Corporation, a drug discovery venture born out of Hokkaido University, initially operated in three business areas: biopharmaceuticals, biosimilars, and cell therapy (regenerative medicine). However, to maximize corporate value and achieve rapid stock price recovery and growth, the company has shifted its strategy to concentrate management resources on the biosimilar business, which provides a stable revenue base, and the cell therapy business, which serves as a growth foundation. In the biosimilar business, the company has been involved in the development of four products, establishing a stable revenue base through sales of launched products. In the cell therapy business, Kidswell Bio is advancing the development of regenerative medicine products utilizing stem cells from deciduous tooth dental pulp (SHED). The company is responsible for manufacturing process development and active pharmaceutical ingredient supply in the biosimilar business, and covers from basic research to manufacturing in the cell therapy business. Both business segments emphasize partnerships with pharmaceutical companies, and the company is actively working to expand its operations.